New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
07:28 EDTPATH, TEVA, ENDPNuPathe says Teva proposal 'reasonably expected' to lead to 'superior proposal'
NuPathe (PATH) disclosed Teva (TEVA) offered to purchase any and all of the shares of NuPathe, at a price per Share of $3.65 per share, net to the seller in cash, plus contractual rights to receive up to an additional $3.15 per share in contingent cash consideration payments payable in the future upon achievement of certain milestones related to ZECUITY. Further, Teva indicated it is prepared to loan the company funds to cover both the company’s ongoing operations pending closing of a transaction and to pay any termination fee due under the existing merger agreement NuPathe has entered with Endo Health Solutions (ENDP). Teva further stated that the Teva proposal will not require additional due diligence, that the Teva offer was unanimously approved by the Teva board of directors, and that there are no financing contingencies with the Teva proposal. NuPathe's board determined that the Teva proposal is :reasonably expected" to lead to a "Superior Proposal," but that pursuant to the terms of the existing merger agreement, NuPathe will continue to recommend that the company’s stockholders tender their shares in the offer by Endo.
News For PATH;TEVA;ENDP From The Last 14 Days
Check below for free stories on PATH;TEVA;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
05:11 EDTTEVAGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
10:06 EDTTEVALannett surges after upbeat Q4, FY14 outlook
Subscribe for More Information
08:50 EDTTEVATeva management to meet with JPMorgan
Meeting to be held in Boston on August 20 hosted by JPMorgan.
August 14, 2014
17:08 EDTTEVASoros Fund Management gives quarterly update on stakes
NEW STAKES: CONSOL Energy (CNX), Google (GOOG), Level 3 (LVLT), Time Warner (TWC), and New Oriental (EDU). INCREASED STAKES: YPF SA (YPF), Apple (AAPL), Facebook (FB), AIG (AIG), and American Airlines (AAL). DECREASED STAKES: Teva (TEVA), Liberty Global (LBTYK), Barrick Gold (ABX), EQT (EQT), and Comcast (CMCSA). LIQUIDATED STAKES: FedEx (FDX), Monster Beverage (MNST), Google (GOOGL), Devon Energy (DVN), Marathon Petroleum (MPC).
12:58 EDTTEVAJANA Partners gives quarterly update on stakes
NEW STAKES: Apache (APA), FMC Corp (FMC), Civeo (CVEO), PetSmart (PETM), and Charter Communications (CHTR). INCREASED STAKES: Actavis (ACT), AIG (AIG), Mallinckrodt (MNK), HD Supply (HDS), and American Capital (ACAS). DECREASED STAKES: Liberty (LVNTA), Oil States International (OIS), eBay (EBAY), Liberty Media (LMCA), and Liberty Interactive (LINTA). LIQUIDATED STAKES: Sirius XM (SIRI), Juniper (JNPR), Golar LNG (GLNG), Outerwall (OUTR), and Teva (TEVA).
07:46 EDTENDPEndo valuation attractive, says Goldman
Subscribe for More Information
August 8, 2014
09:00 EDTENDPBioDelivery Sciences still a takeover target, says Janney Capital
Janney Capital continues to believe that BioDelivery Sciences (BDSI) could be a takeover target, noting that it thinks partner Endo International (ENDP) could be a potential buyer if BioDelivery has more positive top-line results and if the market weakens. The firm, which added that it likes BioDelivery Sciences as a stand-alone company as well, maintains its Buy rating and $15 fair value estimate on the stock.
August 7, 2014
13:55 EDTTEVATeva won't be meaningfully hurt soon by new Copaxone filing, says BMO Capital
After Teva (TEVA) confirmed that it received the first paragraph IV notice for the 3x per week version of its Copaxone drug from Dr. Reddy's (RDY), BMO Capital said it had expected companies to seek to market a generic version of the latest Copaxone formulation, but was surprised that Dr. Reddy's took this action. The firm notes that Teva's decision to file a lawsuit against Dr. Reddy over the application will trigger a 30 month stay of approval of the generic version,. BMIO Capital says that investors should keep this issue on their radar, but the firm does not expect Teva to be meaningfully hurt in the near-term by this development. It keeps an Outperform rating on Teva.
12:06 EDTTEVATeva will continue to defend COPAXONE intellectual property rights
Teva (TEVA) confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE 40 mg/mL product from Dr. Reddy’s Laboratories (RDY). Teva will continue to vigorously defend its COPAXONE intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of FDA approval of Dr. Reddy’s ANDA. COPAXONE 40 mg/mL is protected by two Orange Book patents that expire in 2030.
10:20 EDTTEVAMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use